Erbitux Head And Neck Cancer Application Slated For Third Quarter
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bristol-Myers Squibb and ImClone plan to submit Erbitux for head and neck cancer in the third quarter after an independent review confirmed that a Phase III trial met its primary endpoint